Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Research & Drug Development

1999

Salvati P.; Maj R.; Caccia C.; Cervini M.A.; Lamberti E.; Pevarello P.; Skeen G.A.; White H.S.; Wolf H.H.; Faravelli L.; Mazzanti M.; Mancinelli E.; Varasi M.; Fariello R.G.
Biochemical and Electrophysiological Studies on the Mechanism of Action of PNU-151774E, a Novel Antiepileptic Compound.
J.Pharmac.Exp. Ther.; 288: 1151-1159, 1999

Maj R.; Fariello R.G.; Pevarello P.; Varasi M.; McArthur R.A.; Salvati P.
Anticonvulsant Activity of PNU-151774E in the Amygdala Kindled Model of Complex Partial Seizures.
Epilepsia, 40: 1523-1528, 1999

Pevarello P.; Traquandi G.; Bonsignori A.; McArthur R.A.; Maj R.; Caccia C.; Salvati P.; Varasi M.
Synthesis and Preliminary Biological Evaluation of New a-Amino Amide Anticonvulsants Incorporating a Dextromethorphan Moiety.
Biorg. Med.Lett., 9:1783-1788, 1999

Pevarello P.; Bonsignori A.; Caccia C.; Amici R.; McArthur R.A.; Fariello R.G.; Salvati P.; Varasi M.
Sodium Channel Activity and Sigma Binding of Enantiomeric 2-Aminopropanamide Anticonvulsants.
Biorg. Med. Lett.; 9:2512-2524, 1999

Salvati P.; Maj R.; McArthur R.A.; Cervini M.A.; Kozak W.; Benatti L.; Fariello R.G.
PNU-151774E, a Novel Na+Channel Blocker, Shows Analgesic Effects in Some Animal Models.
Soc. for Neuroscience, Abs 25(2): 1947, 1999

Maj R.; Calabresi M.; Caccia C.; Salvati P.; Fariello R.G.
PNU-151774E, A Combined MAO-B and Glutamate Release Inhibitor, is Effective in Animal Models of Parkinson's Disease
Soc. for Neuroscience, Abs, 25(2): 1599, 1999